NORDIC NANOVECTOR CAPITAL MARKETS DAY 2016 TO HIGHLIGHT STRONG PROGRESS TOWARDS VISION OF BECOMING A SIGNIFICANT PLAYER IN HAEMATOLOGICAL CANCERS
Oslo, Norway, 31 May 2016 Today, Nordic Nanovector ASA (OSE: NANO) hosts a Capital Markets Day in Oslo to provide investors, analysts and press with the opportunity to learn more about the company’s lead antibody-radionuclide conjugate (ARC) product Betalutin®, a potential new treatment for non-Hodgkin’s lymphoma (NHL), its positioning in the NHL therapy market, development plans, as well as future opportunities for value creation based on its ARC platform. The key takeways from today’s presentations are summarised below. Prof. Luigi Zinzani (Associate Professor of Haematology at